PT1356046E - Receptor de citocina zcytor19 - Google Patents

Receptor de citocina zcytor19 Download PDF

Info

Publication number
PT1356046E
PT1356046E PT01988203T PT01988203T PT1356046E PT 1356046 E PT1356046 E PT 1356046E PT 01988203 T PT01988203 T PT 01988203T PT 01988203 T PT01988203 T PT 01988203T PT 1356046 E PT1356046 E PT 1356046E
Authority
PT
Portugal
Prior art keywords
european patent
grant
date
epc
epo
Prior art date
Application number
PT01988203T
Other languages
English (en)
Inventor
Francis J Grant
Theodore E Whitmore
Scott R Presnell
Wenfeng Xu
Julia E Novak
Original Assignee
Zymogenetics L L C
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics L L C, Bristol Myers Squibb Co filed Critical Zymogenetics L L C
Publication of PT1356046E publication Critical patent/PT1356046E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)

Description

DESCRIÇÃO

Claims (1)

  1. REIVINDICAÇÕES
    Europãisches Patentamt European Patent Office Office européen des brevets European Patent Office 80298 MUNICH GERMANY Tel. +49 (0)89 2399 - 0 Fax +49(0)89 2399 - 4465 MacLean, Martin Robert Mathys & Squire LLP 120 Holborn London EC1N2SQ GRANDE BRETAGNE For any questions about this communication: Tel.:+31 (0)70 340 45 00 Date 17.09.09 Reference Application No./Patent No. P25666EP-PCT 01988203.4-2401 /1356046 Applioant/Proprietor ZymoGenetics, L.L.C., et ai Decision to grant a European patent pursuant to Article 97(1) EPC Following examination of European patent application No. 01988203.4 a European patent with the title and the supporting documents indicated in the communication pursuant to Rule 71(3) EPC dated 04.02.09 is hereby granted in respect of the designated Contracting States. The requestfor amendments received at the EPO on 02.06.09 and any subsequent modifications agreed with the applicant have been taken into account. Patent No. Date of filing Priority claimed 1356046 28.11.01 28.11.00/USP 253561 07.02.01/USP 267211 Designated Contracting States and Proprietor(s) : AT BE CH CY DE DK ES Fl FR GB GR ΙΕ IT LI LU MC NL PT SE TR ZymoGenetics, L.L.C. 1201 Eastlake Avenue East Seattle, WA 98102/US AT BE CH CY DE DK ES Fl FR GB GR IE IT LI LU MC NL PT SE TR Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08540/US This decision will take effect on the date on which the European Patent Bulletin mentions the grant (Art. 97(3) EPC). The mention of the grant will be published in European Patent Bulletin 09/42 of 14.10.09. to EPO postal service: 11.09.09 Registered letter EPO Form 2006A 12.07 11.09.09
PT01988203T 2000-11-28 2001-11-28 Receptor de citocina zcytor19 PT1356046E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25356100P 2000-11-28 2000-11-28
US26721101P 2001-02-07 2001-02-07

Publications (1)

Publication Number Publication Date
PT1356046E true PT1356046E (pt) 2010-03-09

Family

ID=26943370

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01988203T PT1356046E (pt) 2000-11-28 2001-11-28 Receptor de citocina zcytor19

Country Status (12)

Country Link
US (10) US20030027253A1 (pt)
EP (1) EP1356046B1 (pt)
JP (1) JP2004532611A (pt)
AT (1) ATE445701T1 (pt)
AU (1) AU2002241533A1 (pt)
CA (1) CA2430485A1 (pt)
CY (1) CY1110921T1 (pt)
DE (1) DE60140213D1 (pt)
DK (1) DK1356046T3 (pt)
ES (1) ES2334888T3 (pt)
PT (1) PT1356046E (pt)
WO (1) WO2002044209A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027253A1 (en) * 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
TW200300170A (en) * 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
EP1497415B1 (en) * 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Methods for detection or modulation of the interaction of a cytokine receptor with its ligand
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
ES2303132T3 (es) 2003-08-07 2008-08-01 Zymogenetics, Inc. Preparaciones homogeneas de il-29.
ATE517914T1 (de) 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
WO2006012644A2 (en) 2004-07-29 2006-02-02 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer
BRPI0613859B8 (pt) 2005-07-26 2021-05-25 Bial Portela & Ca Sa inibidores da comt, seus usos, e composição farmacêutica
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2124947B1 (en) 2007-01-31 2017-07-19 BIAL - Portela & Ca., S.A. Dosage regimen for comt inhibitors
CA2704038A1 (en) * 2007-10-31 2009-05-07 The Scripps Research Institute Combination therapy to treat persistent viral infections
CN105878242A (zh) * 2009-04-01 2016-08-24 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
CN102438595B (zh) * 2009-04-01 2016-04-27 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CN103732610A (zh) * 2011-06-13 2014-04-16 默沙东公司 纯化天然或突变体形式的白喉毒素的方法
PT3604299T (pt) 2011-12-13 2023-10-31 Bial Portela & Ca Sa Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
JP2016519070A (ja) * 2013-03-15 2016-06-30 アッヴィ・インコーポレイテッド 抗体薬物複合体（ａｄｃ）の精製
US9416181B2 (en) 2013-05-06 2016-08-16 Abbvie Inc. Compositions for cell culture and methods of using the same
WO2016033509A1 (en) * 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
CN109641037B (zh) * 2016-04-13 2022-09-06 西安奥瑞单抗生物技术有限公司 抗psma抗体及其用途
WO2023049774A1 (en) * 2021-09-21 2023-03-30 University Of Washington Genetically encoded and exogenously triggered protein-protein ligation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
EP1194549A2 (en) 1999-07-02 2002-04-10 Chiron Corporation Human genes and gene expression products
CN1452633A (zh) * 2000-09-08 2003-10-29 先灵公司 哺乳动物基因、相关试剂及方法
US20030027253A1 (en) 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
CN101531715A (zh) * 2001-04-20 2009-09-16 津莫吉尼蒂克斯公司 细胞因子蛋白质家族
CA2462687A1 (en) 2001-10-02 2003-04-17 Mochida Pharmaceutical Co., Ltd. Novel class ii cytokine receptor
TW200300170A (en) 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
US7820793B2 (en) 2002-02-08 2010-10-26 University Of Medicine And Dentistry Of New Jersey IFN-λ polypeptides and compositions
EP1497415B1 (en) 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Methods for detection or modulation of the interaction of a cytokine receptor with its ligand
EP1575609A4 (en) 2002-10-23 2010-12-15 Zymogenetics L L C METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29
CA2516128A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer

Also Published As

Publication number Publication date
US20070048804A1 (en) 2007-03-01
US20140248661A1 (en) 2014-09-04
CY1110921T1 (el) 2015-06-10
ATE445701T1 (de) 2009-10-15
WO2002044209A2 (en) 2002-06-06
US7601809B2 (en) 2009-10-13
US7618791B2 (en) 2009-11-17
WO2002044209A3 (en) 2003-08-21
US20070048846A1 (en) 2007-03-01
US20110091876A1 (en) 2011-04-21
US20070048799A1 (en) 2007-03-01
DE60140213D1 (de) 2009-11-26
EP1356046A2 (en) 2003-10-29
US20050266485A1 (en) 2005-12-01
US7608452B2 (en) 2009-10-27
AU2002241533A1 (en) 2002-06-11
US20030027253A1 (en) 2003-02-06
JP2004532611A (ja) 2004-10-28
EP1356046B1 (en) 2009-10-14
DK1356046T3 (da) 2010-03-01
CA2430485A1 (en) 2002-06-06
US20070117165A1 (en) 2007-05-24
ES2334888T3 (es) 2010-03-17
US20120064571A1 (en) 2012-03-15
US20070111942A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
PT1356046E (pt) Receptor de citocina zcytor19
Coleman et al. Regulation of mouse peritoneal mast cell secretory function by stem cell factor, IL-3 or IL-4.
Gaidano et al. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen
McKinstry et al. Cytokine receptor expression on hematopoietic stem and progenitor cells
Soejima et al. A functional IFN-γ-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan
Lüttichau et al. A highly selective CC chemokine receptor (CCR) 8 antagonist encoded by the poxvirus molluscum contagiosum
Jostock et al. Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Müllberg et al. IL-6 receptor independent stimulation of human gp130 by viral IL-6
Foss et al. Frequent expression of the B-cell–specific activator protein in Reed-Sternberg cells of classical Hodgkin’s disease provides further evidence for its B-cell origin
Lee et al. Induction of interleukin 2 receptor (TAC) by tumor necrosis factor in YT cells.
Kollet et al. The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34+ CD38−/low cells capable of repopulating severe combined immunodeficiency mice
Tweardy et al. Granulocyte colony-stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells
Andjelkovic et al. Expression of binding sites for β chemokines on human astrocytes
Kuter et al. Thrombopoiesis and thrombopoietins: molecular, cellular, preclinical, and clinical biology
Drexler et al. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells
EP1555318A3 (en) Hematopoietic cytokine receptor
WO2002000721A8 (en) Cytokine receptor zcytor17
NZ510744A (en) Cytokine receptor zalpha11
Gruss et al. Hodgkin's Disease: A Cytokine-Producing Tumor− A Review
Schneider et al. Immunoblastic sarcoma of T-and B-cell types: morphologic description and comparison
Viardot et al. The human immunodeficiency virus (HIV)-type 1 coreceptor CXCR-4 (fusin) is preferentially expressed on the more immature CD34+ hematopoietic stem cells
Ruiz et al. CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T‐cell lymphoma
Reya et al. Regulated expression and function of CD122 (interleukin-2/interleukin-15R-beta) during lymphoid development
Allavena et al. Migratory response of human NK cells to monocyte-chemotactic proteins
Yamaguchi et al. Down-regulation of interleukin 6 receptors of mouse myelomonocytic leukemic cells by leukemia inhibitory factor.